IP Library › Granted Patent US 8,106,005
Granted Patent B2
US 8,106,005 · App. 12/617,639 · Granted Jan 31, 2012

Modulating apoptosis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,106,005
App. No.
12/617,639
Granted
Jan 31, 2012
Kind
B2
Abstract

The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries.

Claims (7)

1. A method of treating apoptosis-mediated tissue damage in a subject, the method comprising administering to a subject in need thereof a composition comprising flagellin, wherein the apoptosis is attributable to cellular stress.

2. The method of claim 1 wherein the composition is administered prior to, together with, or after the tissue damage.

3. The method of claim 1 , wherein the cellular stress is radiation, and wherein the composition is administered in combination with a radioprotectant.

4. The method of claim 3 wherein the radioprotectant is an antioxidant.

5. The method of claim 4 wherein the antioxidant is selected from the group consisting of amifostine and vitamin E.

6. The method of claim 3 , wherein the radioprotectant is a cytokine.

7. The method of claim 6 , wherein the cytokine is stem cell factor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2013
From: GUDKOV, ANDREI V.
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 030500/0612 →